# Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Source: https://onco.cc/trials/nct06190899/  
OnCo record `nct06190899` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Gedatolisib, Darolutamide in prostate cancer, run by Celcuity Inc, now recruiting.

## Summary

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer is a phase 1/2 interventional study registered as NCT06190899 by Celcuity Inc, with 54 participants planned, started 2024-01-01 and due to reach its primary completion in 2028-01. Interventions recorded: Gedatolisib, Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male, Urogenital Diseases, Male, Prostatic Disease. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06190899
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label, Randomized, Dose Finding and Dose Expansion Study of Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Sponsor: Celcuity Inc
- Enrolled: 54

## Sources

- ClinicalTrials.gov NCT06190899: https://clinicaltrials.gov/study/NCT06190899

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Darolutamide](https://onco.cc/drugs/darolutamide/), [Gedatolisib](https://onco.cc/drugs/gedatolisib/)
- companies: [Celcuity](https://onco.cc/companies/celcuity/)

---
JSON: https://onco.cc/api/v1/entities/nct06190899.json